Clearmind Medicine Inc. - Common Shares (CMND)
CMND moved a median of -1.21% 30 minutes after news, and -1.77% by the close. How CMND actually reacts to news — the realized, point-in-time move the market made, measured across 401 labeled events over the last three years with zero look-ahead.
CMND’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.47% | 33% | 390 |
| 30-min | -1.21% | 36% | 398 |
| 60-min | -1.14% | 33% | 399 |
| to close | -1.77% | 31% | 396 |
| Middle 50% of CMND reactions | -4.03% to +1.14% |
|---|---|
| Median reaction (30-min) | -1.21% |
| Measured reactions | 401 |
Half of all Clearmind Medicine Inc. - Common Shares news events land between -4.03% and +1.14% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when CMND moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to CMND's baseline. Nothing else.
Recent CMND events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 6-K Clearmind Medicine Inc. For: Oct 16 | SEC filing · Form 6-K | SEC EDGAR | — | — | |
| Form 6-K Clearmind Medicine Inc. For: Oct 13 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -4.15% | |
| Clearmind: Charging Robotics Launches Next-Generation Automated EV-Charging Technology for Robotaxis and Autonomous Fleets | Press release | GlobeNewswire | +0.00% | +0.31% | |
| Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder | Press release | GlobeNewswire | +0.75% | -0.60% | |
| Form 6-K Clearmind Medicine Inc. For: Oct 08 | SEC filing · Form 6-K | SEC EDGAR | +0.75% | -0.60% | |
| Clearmind Advances Dialogue with U.S. Federal Government on Psychedelic Therapies, Submitting Recommendations to FDA | Press release | GlobeNewswire | -2.61% | +14.78% | |
| Form 6-K Clearmind Medicine Inc. For: Oct 07 | SEC filing · Form 6-K | SEC EDGAR | -2.61% | +14.78% | |
| Form 6-K Clearmind Medicine Inc. For: Sep 30 | SEC filing · Form 6-K | SEC EDGAR | +0.35% | -4.54% | |
| Clearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine Combinations | Press release | GlobeNewswire | -2.97% | +5.72% | |
| Form 6-K Clearmind Medicine Inc. For: Sep 23 | SEC filing · Form 6-K | SEC EDGAR | -2.97% | +5.72% | |
| Clearmind Medicine Delivers Briefing to FDA Following Invitation to Historic Psychedelic Hearing in Washington, D.C. | Press release | GlobeNewswire | +3.75% | +3.51% | |
| Form 6-K Clearmind Medicine Inc. For: Sep 17 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -5.95% | |
| Form 6-K Clearmind Medicine Inc. For: Sep 14 | SEC filing · Form 6-K | SEC EDGAR | -0.53% | +0.43% | |
| Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial | Press release | GlobeNewswire | -2.38% | -3.31% | |
| Form 6-K Clearmind Medicine Inc. For: Jul 31 | SEC filing · Form 6-K | SEC EDGAR | -2.38% | -3.31% | |
| Clearmind Medicine Receives Yale IRB Approval, Enabling Patient Recruitment for Parts B and C of CMND-100 Phase I/II Trial, Following Positive Safety Results | Press release | GlobeNewswire | -12.16% | -10.44% | |
| Form 6-K Clearmind Medicine Inc. For: Sep 08 | SEC filing · Form 6-K | SEC EDGAR | -12.16% | -10.44% | |
| Clearmind Medicine Signs Definitive Agreement to Acquire 51% Stake in Wireless Charging Company for Automated Parking and Robotaxis | Press release | GlobeNewswire | -0.67% | -22.15% | |
| Form 6-K Clearmind Medicine Inc. For: Sep 04 | SEC filing · Form 6-K | SEC EDGAR | -0.67% | -22.15% | |
| Form 6-K Clearmind Medicine Inc. For: Sep 02 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -6.08% | |
| Clearmind Reaches Key Milestone: CMND-100 Phase IIa now Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled | Press release | GlobeNewswire | -2.00% | -5.18% | |
| Form 6-K Clearmind Medicine Inc. For: Sep 01 | SEC filing · Form 6-K | SEC EDGAR | -2.00% | -5.18% | |
| Clearmind Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation | Press release | GlobeNewswire | -2.28% | -4.00% | |
| Form 6-K Clearmind Medicine Inc. For: Aug 24 | SEC filing · Form 6-K | SEC EDGAR | — | +2.40% | |
| Clearmind Advances CMND-100 to Alcohol Use Disorder Patients After Achieving Primary Safety Endpoint | Press release | GlobeNewswire | +4.14% | +9.47% | |
| Clearmind Medicine Announces Positive Permeation Results for Intranasal MEAI Formulation, Supporting Enhanced Nasal Retention Without Compromising Drug Delivery | Press release | GlobeNewswire | -0.31% | +1.26% | |
| Form 6-K Clearmind Medicine Inc. For: Aug 11 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +2.48% | |
| Clearmind Reaches Key Clinical Trial Milestone as DSMB Unanimously Clears Progression in AUD Study | Press release | GlobeNewswire | +0.57% | +0.57% | |
| Form 6-K Clearmind Medicine Inc. For: Aug 06 | SEC filing · Form 6-K | SEC EDGAR | +0.49% | -6.32% | |
| Clearmind Medicine Signs Letter of Intent to Acquire 51% Majority Stake in EV Wireless Charging Solutions for Automated Parking Systems Company | Press release | GlobeNewswire | -0.32% | +5.16% | |
| Form 6-K Clearmind Medicine Inc. For: Aug 03 | SEC filing · Form 6-K | SEC EDGAR | -0.32% | +5.16% | |
| Clearmind Announces Positive Safety Findings for CMND 100, Demonstrating Consistent Tolerability Throughout Full Dose Escalation in Part A of its FDA-Regulated Clinical Trial | Press release | GlobeNewswire | -1.36% | +10.20% | |
| Form 6-K Clearmind Medicine Inc. For: Jul 30 | SEC filing · Form 6-K | SEC EDGAR | -0.61% | +3.68% | |
| Clearmind Medicine Successfully Completes Part A of its FDA Regulated Phase I/II Trial | Press release | GlobeNewswire | -2.56% | -6.41% | |
| Clearmind Medicine Expends Global IP portfolio with Hong Kong Patent Filing for Novel Psychedelic Compounds; Targets Multi-Billion-Dollar PTSD Therapeutics Market | Press release | GlobeNewswire | -2.33% | -3.11% | |
| Form 6-K Clearmind Medicine Inc. For: Jul 20 | SEC filing · Form 6-K | SEC EDGAR | -1.12% | -8.38% | |
| Clearmind Medicine Commends Federal Momentum in Advancing Psychedelic-Based Therapies for Mental Health and Addiction | Press release | GlobeNewswire | -1.58% | +2.10% | |
| Form 6-K Clearmind Medicine Inc. For: Jul 17 | SEC filing · Form 6-K | SEC EDGAR | -2.33% | -3.11% | |
| Clearmind Medicine Reports Positive Retention Results for Intranasal Formulation of its Psychedelic-Based Neuroplastogen MEAI | Press release | GlobeNewswire | -2.16% | +7.57% | |
| Form 6-K Clearmind Medicine Inc. For: Jul 16 | SEC filing · Form 6-K | SEC EDGAR | -0.99% | -0.99% | |
| Clearmind Shares Promising Real-World Insights from Ongoing CMND-100 First-in-Human Trial | Press release | GlobeNewswire | +0.00% | +0.00% | |
| Form 6-K Clearmind Medicine Inc. For: Jul 13 | SEC filing · Form 6-K | SEC EDGAR | +0.64% | -2.03% | |
| Clearmind Medicine Responds to the U.S. Administration’s RFI for Addiction Treatment Innovations as Part of the Great American Recovery Initiative | Press release | GlobeNewswire | +1.45% | -1.93% | |
| Form 6-K Clearmind Medicine Inc. For: Jul 10 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +0.00% | |
| Clearmind Reports Successful Formulation Feasibility Study Supporting Potential New Additional Route of Administration Development for MEAI | Press release | GlobeNewswire | +0.48% | +0.95% | |
| Form 6-K Clearmind Medicine Inc. For: Jul 07 | SEC filing · Form 6-K | SEC EDGAR | -0.73% | +2.44% | |
| Clearmind Medicine Advances Its Innovation with Newly Granted U.S. Patent, Enhancing Global Patent Strength | Press release | GlobeNewswire | -7.46% | -1.92% | |
| Form 6-K Clearmind Medicine Inc. For: Jun 29 | SEC filing · Form 6-K | SEC EDGAR | -7.46% | -1.92% | |
| Clearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA-Regulated Phase I/II Trial | Press release | GlobeNewswire | -1.30% | -3.25% | |
| Form 6-K Clearmind Medicine Inc. For: Jun 22 | SEC filing · Form 6-K | SEC EDGAR | -1.30% | -3.25% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the CMND section they belong to.
Where else CMND is measured.
CMND earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Clearmind Medicine Inc. - Common Shares's median reaction calculated?
Every labeled CMND news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 401 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 36% of CMND's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does CMND's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.